Erosive oesophagitis: Outcome of repeated long term maintenance treatment with low dose omeprazole 10 mg or placebo

Gut

Volumn 43, Issue 4, 1998, Pages 458-464

  Bardhan, K D ^a   Cherian, P ^a   Vaishnavi, A ^a   Jones, R B ^a   Thompson, M ^a   Morris, P ^a   Brooks, A ^a   D'Silva, J ^a   Gillon, K R W ^b   Wason, C ^b   Patterson, J ^b   Polak, J ^c   Bishop, A ^c  

^a Rotherham NHS Foundation Trust   (United Kingdom)

^b Astra Clinical Research Unit   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Erosive oesophagitis; Long term maintenance treatment; Omeprazole

Indexed keywords

OMEPRAZOLE;

ARTICLE; CLINICAL TRIAL; DRUG EFFICACY; ESOPHAGITIS; FEMALE; HEALING; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RELAPSE; REMISSION; STOMACH PH; TREATMENT OUTCOME;

EID: 7344254043     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.43.4.458     Document Type: Article

References (24)

1. Facer P, Bishop AE, Lloyd RV, et al. Chromogranin: a newly organised marker for endocrine cells of the human gastrointestinal tract. Gastroenterology 1985;89:1366-73.
2. Grimelius L. A silver nitrate stain for A2 cells in human pancreatic pilots. Acta Soc Med Upsal 1968;73:243-70.
3. Sevier AC, Munger BC. A silver method for paraffin of neural tissue. J Neuropathol Exp Nuerol 1965;24:130-5.
4. Solcia E, Bordi C, Creutzfeldt W, et al. Histopathological classification of non-antral gastric endocrine growths in man. Digestion 1988;41:185-200.
5. Briant MG, Adrian TE. Gastrin. In: Bloom SR, Long RG, eds. Radio-immunoassay of gut regulatory peptide. London: WB Saunders, 1982:51-9.
6. Collet D. Modelling survival data in medical research. London: Chapman and Hall, 1994.
7. Maratka Z. Terminology, definitions and diagnostic criteria in digestive endoscopy. Scand J Gastroenterol 1984;19(suppl 103):1-74.
8. Staerk Laursen L, Havelund T, Bondesen S, et al. Omeprazole in the long-term treatment of gastro-oesophageal reflux disease. A double-blind randomised dose-finding study. Scand J Gastronterol 1995;30:839-46.
9. Sharma BK, Walt RP, Pounder RE, et al. Optimal dose of oral omeprazole for maximal 24 hour decrease of intragastric acidity. Gut 1984;25:957-64.
10. McLauchlan G, Crean GP, McColl KEL. Effect of low-dose omeprazole on gastric acid secretion in duodenal ulcer patients. Aliment Pharmacol Ther 1988;2:263-8.
11. Naesdal J, Bodemar G, Walan A. Effect of omeprazole, a substituted benzimidazole, on 24h intragastric acidity in patients with peptic ulcer disease. Scand J Gastroenterol 1984;19:916-22.
12. Bardhan K D. Omeprazole in the treatment of gastroesophageal reflux disease. In: Scarpignato C. Advances in drug therapy of gastroesophageal reflux disease. From Gastrointestinal Res 1992;20:246-306.
13. Sandmark S, Carlsson R, Fausa O, et al. Omeprazole or ranitidine in the treatment of reflux esophagitis. Scand J Gastroenterol 1988;23:625-32.
14. Hallerbäck B, Unge P, Carling L, et al, and the Scandinavian Clinics for United Research Group. Omepraxole or ranitidine in long-term treatment of reflux esophagitis. Gastroenterology 1994;107:1305-11.
15. Bate CM, Booth SN, Crowe JP, et al and the SOLO investigator group. Omeprazole 10 mg or 20 mg once daily in the prevention of recurrence of reflux esophagitis. Gut 1995;36:492-8.
16. Laurent J, Cassan P, Rev JF, et al. Efficacy of omeprazole 20mg followed by maintenance treatment with omeprazole 10mg for the relief and prophylaxis against recurrence of GERD symptoms in patients with low grade esophagitis [abstract]. Gastroenterology 1995;108:A145.
17. Carlsson R, Galmiche J-P, Dent J, et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omepraxole trials. Aliment Pharmacol Ther 1997; 11:473-82.
18. Lundell L, Backman L, Ekström P, et al. Prevention of relapse of reflux esophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991;26:248-56.
19. Hetzel DJ, Carlsson R, Dent J, et al. Relapse of esophagitis after endoscopic healing: an analysis of unfavourable prognostic factors. Scand J Gastroenterol 1989;24:(suppl 166): A175.
20. Lamberts R, Creutzfeldt VT, Strüber HG, et al. Long term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth and gastritis. Gastroenterology 1993; 104:1356-70.
21. Diebold MD, Richardson S, Zeitoun P, et al, and colleagues in 52 centres. Influence of the degree of severity of fundic gastritis on serum gastrin concentration and ECL cell density in controls and during prolonged treatment with antisecretory drugs [abstract]. Gastroenterology 1995;108: A83.
22. Howden CW, Derodra JK, Burget DW, et al. Effects of low dose omeprazole on gastric secretion and plasma gastrin in patients with healed duodenal ulcer. Hepatogastroenterology 1986;33:267-70.
23. Hemery P, Galmiche J-P, Roze C, et al. Low dose omeprazole effects on gastric acid secretion in normal man. Gastroenterol Clin Biol 1987;11:148-53.
24. Prichard PJ, Yeomans ND, Shulkes A, et al. The effect of omeprazole on 21 hour intragastric pH and fasting plasma gastrin during low dosage (10 mg) in the morning or the evening. J Gastroenterol Hepatol 1986;1:289-95.